Inflammatory, cardio-metabolic and diabetic profiling of chronic schizophrenia
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Background: There is a growing interest in low-grade inflammatory and metabolic alterations in patients with chronic schizophrenia (SCH). Methods: Inflammatory (tumor-necrosis factor-α [TNF-α], interferon-γ [IFN-γ], interleukins [IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10], monocyte chemo-attractant protein-1 [MCP-1]) and growth factors (vascular endothelial growth factor [VEGF], epidermal growth factor [EGF]) were measured in blood serum samples of 105 SCH patients and 148 control subjects (CS). Simultaneously the clinical biomarkers (C-reactive protein [CRP], triglycerides [TG], low-density lipoprotein [LDL-c] and high-density lipoprotein [HDL-c] cholesterol, glycated hemoglobin [HbA1c]) were measured, and body mass index (BMI) was calculated for patients. Results: Several cyto-/chemokines (IFN-γ, MCP-1, IL-2, IL-6, IL-8 and IL-10) were significantly (P< 0.0000001) elevated in SCH patients compared to CS. Odds ratios, obtained from logistic regression analyses, were significantly elevated for IL-2, IL-6, IL-10, INF-γ, and decreased for TNF-α in SCH group. Among the patients, higher IL-2, IL-6, INF-γ and lower MCP-1 levels as well as male gender were together significant (P< 0.000001) predictors of higher HbA1c levels, and TG/HDL-c parameter was associated with ratios of INF-γ/IL-10 (P= 0.004), and INF-γ/IL-4 (P= 0.049), HbA1c (P= 0.005), INF-γ (P= 0.009), as well as LDL-c (P= 0.02) levels. Conclusions: IL-2, IL-6, IL-10 and IFN-γ were the most significant SCH-related markers among the measured cytokines in our patient group. Furthermore, significant associations between pro-/anti-inflammatory imbalance and HbA1c as well as cardio-metabolic risk marker (TG/HDL-c) were observed, indicating higher risks of diabetes and cardiovascular diseases among SCH patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interferon-γ: an overview of signals, mechanisms and functions
Schroder, K., Hertzog, P. J., Ravasi, T., & Hume, D. A. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0603252 · Cited by 4,120 · cited 1×
“IFN-g is an important activator of macrophages, its aberrant expression has been associated with a number of auto-inflammatory and autoimmune diseases, and it is critical for innate and adaptive immunity against viral and intracellular bacterial infections [48].”
BackgroundInflammatory Mechanisms in Obesity
Gregor, M. F., & Hotamisligil, G. S. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101322 · Cited by 3,754 · cited 1×
“According to international clinical guidelines [74], HbA1c level is a reliable marker for assessing both a patient’s pre-diabetic/ diabetic state and to evaluate the efficacy of any anti-diabetic treatment.”
BackgroundMeta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects
Miller, B. J., Buckley, P., Seabolt, W., Mellor, A., & Kirkpatrick, B. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.04.013 · Cited by 1,742 · cited 7×
“For example, an elevation of IL-6 is noted by almost all studies irrespective of the stage of disease or antipsychotic treatment [33].”
BackgroundResultInfluentialCommon variants conferring risk of schizophrenia
†Genetic Risk and Outcome in Psychosis (GROUP), Stefansson, H., Ophoff, R. A., Steinberg, S., Andreassen, O. A., Cichon, S., Rujescu, D., Werge, T., Pietiläinen, O. P. H., Mors, O., et al. (2009) · Nature · doi:10.1038/nature08186 · Cited by 1,677
Tiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354
Global guideline for type 2 diabetes
(2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.10.001 · Cited by 1,064
Fillman, S. G., Cloonan, N., Catts, V. S., Miller, L. C., Wong, J., McCrossin, T., Cairns, M., & Weickert, C. S. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.110 · Cited by 609
Twenty-five year mortality of a community cohort with schizophrenia
Brown, S., Kim, M., Mitchell, C., & Inskip, H. (2010) · British Journal of Psychiatry · doi:10.1192/bjp.bp.109.067512 · Cited by 601
Association of Schizophrenia and Autoimmune Diseases: Linkage of Danish National Registers
Eaton, W. W., Byrne, M., Ewald, H., Mors, O., Chen, C.-Y., Agerbo, E., & Mortensen, P. B. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.3.521 · Cited by 527
Cytokines and schizophrenia: microglia hypothesis of schizophrenia
Monji, A., Kato, T., & Kanba, S. (2009) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2009.01945.x · Cited by 508 · cited 1×
“Although the mechanism that underlies obesity in people with SCH is not completely clear, antipsychotic medications, chronic low-grade inflammation, lifestyle, and genetic vulnerability are suggested as risk factors for overweight [72,73].”
Background
Cited by
Cytokine Alterations in Schizophrenia: An Updated Review
Momtazmanesh, S., Zare-Shahabadi, A., & Rezaei, N. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00892 · Cited by 276
Department of Psychological Medicine, K. C. L., Hussein, S., Himmerich, H., Department of Psychiatry, P. A. P., Willmund, G. D., Department of Psychiatry, P. A. P., Ibrahim, M. A. A., Department of Immunological Medicine and Allergy, K. H. P., Dalton, B., & Department of Psychological Medicine, K. C. L. (2017) · Psychiatria Danubina · doi:10.24869/psyd.2017.407 · Cited by 26
Monocyte/HDL Cholesterol Ratios as a New Inflammatory Marker in Patients with Schizophrenia
Kılıç, N., Tasci, G., Yılmaz, S., Öner, P., & Korkmaz, S. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13020276 · Cited by 15
“It was shown in another study with cytokines that low-level inflammation increases the cardiometabolic risk [37].”
Result
Metadata
- Authors
- Balõtšev, R., Koido, K., Vasar, V., Janno, S., Kriisa, K., Mahlapuu, R., Ljubajev, U., Parksepp, M., Veiksaar, P., Volke, V., Lang, A., Haring, L., Zilmer, M., & Vasar, E.
- Venue
- European Psychiatry
- Publisher
- Cambridge University Press (CUP)
- Published
- 2017-01
- Volume
- 39
- Pages
- 1-10
- ISSN
- 0924-9338 (ISSN-L)
- 1778-3585
- OpenAlex
- W2547285684
- Cited by
- 64
- References
- 14
- FWCI
- 1.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inflammatory, cardio-metabolic and diabetic profiling of chronic schizophrenia. https://app.cochat.ai/papers/10.1016/j.eurpsy.2016.05.010
- The paper
- Balõtšev, R., Koido, K., Vasar, V., Janno, S., Kriisa, K., Mahlapuu, R., Ljubajev, U., Parksepp, M., Veiksaar, P., Volke, V., Lang, A., Haring, L., Zilmer, M., & Vasar, E. (2017). Inflammatory, cardio-metabolic and diabetic profiling of chronic schizophrenia. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2016.05.010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.